Silence Therapeutics plc (OTCMKTS:SLNCF) Short Interest Down 94.8% in May

Silence Therapeutics plc (OTCMKTS:SLNCF) was the recipient of a large decrease in short interest in May. As of May 15th, there was short interest totaling 39 shares, a decrease of 94.8% from the April 30th total of 755 shares. Based on an average daily volume of 784 shares, the short-interest ratio is presently 0.0 days.

Silence Therapeutics Stock Performance

OTCMKTS SLNCF opened at $1.06 on Thursday. The firm’s 50 day simple moving average is $1.99 and its 200 day simple moving average is $1.80. Silence Therapeutics has a 1 year low of $1.06 and a 1 year high of $2.63.

About Silence Therapeutics

Silence Therapeutics is a clinical-stage biotechnology company focused on the development of small interfering RNA (siRNA) therapies designed to silence disease-causing genes. The company’s proprietary AtuRNAi platform employs ligand-conjugated siRNA to enable targeted delivery and extended duration of action, with the aim of addressing chronic and severe diseases. Silence Therapeutics advances its own pipeline programs while also forming strategic partnerships to leverage its delivery technology in indications such as cardiovascular disease, metabolic disorders and rare genetic conditions.

The company’s lead program, SLN360, is designed to reduce lipoprotein(a), a known independent risk factor for cardiovascular events, and is currently in clinical development.